New drug combo targets tumors in patients with organ failure

NCT ID NCT01366144

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney problems. The goal is to find a safe dose and see how the body processes the drugs in these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm cancer cancer of unknown primary site carcinoma of esophagus endometrial carcinoma endometrium neoplasm Esophageal Neoplasms head and neck cancer Head and Neck Neoplasms kidney failure liver failure lung carcinoma lung neoplasm melanoma metastatic malignant neoplasm Neoplasm Metastasis Neoplasms, Unknown Primary ovarian cancer ovarian carcinoma testicular cancer transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA CARCINOMA OF UNKNOWN PRIMARY ENDOMETRIAL CARCINOMA ESOPHAGEAL CARCINOMA LIVER FAILURE LUNG CARCINOMA MALIGNANT HEAD AND NECK NEOPLASM MALIGNANT TESTICULAR NEOPLASM MELANOMA METASTATIC MALIGNANT SOLID NEOPLASM OVARIAN CARCINOMA RENAL FAILURE UNRESECTABLE MALIGNANT NEOPLASM UROTHELIAL CARCINOMA

Contacts and locations

Locations

Case Western Reserve University

Cleveland, Ohio, 44106, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
City of Hope South Pasadena

South Pasadena, California, 91030, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467, United States
Montefiore Medical Center-Weiler Hospital

The Bronx, New York, 10461, United States
Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, 17033-0850, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.